Investigators note that although the overall cost for implementing next-generation sequencing (NGS) testing would be more than implementing current polymerase chain reaction (PCR)–based testing, the ...
Addition of next generation sequencing research panels, bioinformatics, positions IDT to become a leading oncology research solutions provider “The acquisition of the NGS research assays aligns with ...
NCI-MATCH next-generation sequencing assay for detecting genetic mutations in tumors is sensitive, specific, and reproducible, reports The Journal of Molecular Diagnostics One of the most promising ...
Addressing high costs and improving reimbursement frameworks are critical challenges but localizing workflows in underserved ...
Pan-Cancer Interrogation of MUTYH Variants Reveals Biallelic Inactivation and Defective Base Excision Repair Across a Spectrum of Solid Tumors Clinically relevant actionable mutations were identified ...
Comparative genomic landscape of patients with lung cancer with high-load versus low-load Epstein-Barr virus infection. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This ...
The global next generation sequencing (NGS) market is expected to register a robust CAGR of around 15% over the next five years. This growth is primarily driven by the rising adoption of precision ...
New methods of testing tissue and plasma beyond next-generation sequencing (NGS) could be used to deliver the best ...
Illumina has launched Protein Prep, an assay that measures up to 9,500 unique human protein targets using next-generation sequencing (NGS). The platform is designed to integrate proteomic data into ...
Precision medicine is key to developing more effective and less toxic treatments, representing the present and future of oncology research. This approach offers significant promise for incremental ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback